Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Radiation Plus Hormone Therapy for Locally Advanced Prostate Cancer Improves Survival
(Posted: 02/03/2009) - Clinical trial results published online December 15, 2009, in The Lancet, affirms earlier studies showing that adding radiation therapy to hormone therapy (HT) is more effective than HT alone for locally advanced prostate cancer.
- 5-FU-Based Chemotherapy Cures Some Patients with Colon Cancer
(Posted: 02/03/2009) - Researchers from the Adjuvant Colon Cancer Endpoints (ACCENT) Group used individual patient data from 18 phase III trials of adjuvant 5-FU-based chemotherapy for colon cancer to show that the regimens provide their survival benefit primarily by reducing the high risk of recurrence within the first two years after surgery, according to a study published online January 5, 2009, in the Journal of Clinical Oncology.
- Surgery Alone May Be Best for Early Endometrial Cancer
(Posted: 01/14/2009) - Results from a large international clinical trial show no evidence of benefit in terms of overall or recurrence-free survival for pelvic lymphadenectomy in women with early endometrial cancer, according to the Jan. 10, 2009, issue of the Lancet.
- Depression Management Effective in Low-Income Hispanic Cancer Patients
(Posted: 11/20/2008) - A collaborative-care intervention to treat depression in cancer patients was more effective than usual care in relieving symptoms of depression among low-income Hispanics, according to the Sept. 20, 2008, Journal of Clinical Oncology.
- High Dose Chemotherapy Significantly Prolongs Survival for Patients with Acute Myeloid Leukemia
(Posted: 11/17/2008) - Preliminary results from a large, randomized clinical trial for patients ages 16 to 60 with previously untreated acute myeloid leukemia, a cancer of the blood and bone marrow, show that patients who received a high dose of a commercially available chemotherapy drug, daunorubicin, during initial therapy lived longer than patients who received a standard dose of the same drug.